People

Healthcare executive who previously led business operations at PillPack and Amazon Pharmacy before joining Headlight.

Jim Zhao is named in Prenosis’ shared biography directory with the external caption Senior R&D Director, Foxconn Interconnect Technologies. A company employment, directorship or advisory appointment at Prenosis is not established by that caption.

Robin Carver has clinical and commercial experience in acute-care technology, including previous vice-president work at Premier and nursing education at East Carolina and UNC.

Brian Bray develops clinical information systems, clinical data warehouses and hospital integration tools. Before his Prenosis appointment he worked as a clinical-data integration architect at Verily.

Jim Sianis has commercial healthcare-data and pharmaceutical experience, including PINC AI’s Healthcare Database and Merck. He trained in pharmacy at Temple and business at Penn State.

William Harty specializes in healthcare interoperability and enterprise medical-software integration. His Prenosis biography describes infection-surveillance software and computer-science and business training at Vermont.

Nam Nguyen is an informatics adviser published by Prenosis. His biography describes healthcare data management, clinical decision support and analytics-platform experience at IMS Health, Practice Fusion, Allscripts and Veradigm. His identity is kept separate from the existing DeepWork Capital investor with the same name.

Suzanne Lebold advises biopharma businesses on strategy, licensing and acquisitions after business-development leadership at Abbott and AbbVie.

Rashid Bashir co-founded Prenosis and advises the company. An Illinois bioengineering professor and engineering dean, he researches biological engineering and has earlier semiconductor-commercialization experience.

Ruoqing Zhu researches personalized medicine, survival analysis, reinforcement learning and statistical machine learning. He trained at UNC and Yale before joining Illinois.

David Sihai Zhao develops statistical methods for large biological datasets, genomics and multi-omics analyses. He trained in biostatistics at Harvard.

Philip Verhoef is an adult and pediatric critical-care physician and immunology researcher whose work includes sepsis biology, laboratory models and clinical datasets.

Pratik Sinha is a physician-scientist studying precision treatment in sepsis and acute respiratory distress syndrome. He trained in the UK and Australia and undertook doctoral work at Imperial College London.

Edward Ogunro previously led scientific research and development at Hospira and held hospital-products and diagnostics leadership positions at Abbott.

Sean Murphy previously led corporate M&A and business development at Abbott, co-founded Malin Life Sciences and worked at Evercore.

Gary Kurtzman is a physician, biotechnology entrepreneur and healthcare investor whose previous work includes Safeguard Scientifics, BioAdvance and Gilead Sciences.

Nathan Shapiro is an emergency-medicine clinician and researcher. Prenosis’ biography describes his Harvard and Beth Israel research work, sepsis studies and experience evaluating clinical biomarkers.

Avinash Sastry leads engineering at Prenosis. His experience spans software, firmware, quality assurance, architecture and regulated medical-device software, including AI healthcare systems.

Meghann Howland leads clinical work at Prenosis after clinical research leadership at PanCan, Iqvia Biotech and Worldwide Clinical Trials. Her experience includes emergency and critical care nursing.

Carlos Lopez-Espina has helped develop Prenosis’ biological and clinical data platform. His earlier work spans medical devices, diagnostics, regulatory clearances and commercial launches; he studied aeronautical and mechanical engineering.

Angela Thomas is Prenosis’ Chief Financial Officer. Her previous work includes biotechnology-company finance and public accounting, including Sony Biotechnology and PwC. She studied public accounting at Illinois Wesleyan University and business administration at the University of Florida.

Bobby Reddy co-founded Prenosis and leads its strategy, clinical partnerships and product development. He trained in electrical engineering at Illinois and UC Irvine.

Sarah Haberman leads community and impact at Unlikely Collaborators, overseeing grant-making strategy and operations and partnerships with grantees, researchers and practitioners. Previously CEO of The Moth from 2013 to 2026 and a development leader at New York cultural and educational institutions.

Elizabeth R. Koch is a writer and social entrepreneur who founded Unlikely Collaborators and developed its Perception Box framework for exploring beliefs, identity and experience. Her own biography separately identifies her founding work with Tiny Blue Dot Foundation and The Elizabeth R. Koch Foundation; those organizations are not merged with Unlikely Collaborators.

Stacey Ferguson is a marketing and communications executive, community builder and startup founder. Her May2022 guest biography identifies her Genius Guild marketing role and earlier JusticeFergie and Blogalicious work; this is retained as historical affiliation.

Brian Laung Aoaeh co-founded REFASHIOND Ventures and the Worldwide Supply Chain Federation. His Genius Guild residency was announced in November2021. His later career investment count and REFASHIOND rolling-fund capital are not attributed to Genius Guild.

Tessa Flippin founded Capitalize VC after venture investing at TechNexus and founding fintech payments platform La Plataforma. Genius Guild announced her one-year venture-capital residency in November2021; no present residency status is inferred.

Saidah Nash Carter works on digital innovation, inclusive business and impact. Her own biography describes Reuters NewMedia work and co-founding Bright Insights Global. Genius Guild publishes her affiliation, but does not disclose a current title.

Kathryn Finney founded Genius Guild and leads its venture investing. She previously founded digitalundivided and The Budget Fashionista, is a Yale-trained public-health professional and wrote Build the Damn Thing. Her own biography describes investments across her career; this is not treated as the complete Genius Guild portfolio.

AI specialist and technology entrepreneur published as Collab Capital’s inaugural AI Executive-in-Residence in June2025. The firm describes her as a former Amazon AI leader supporting portfolio companies with on-demand AI expertise; exact appointment dates and continued tenure are undisclosed.

Public-relations consultant named as an external media contact for Collab Capital’s June2025 Fund II close announcement. The dated source establishes that engagement; an ongoing employee role or current assignment is not confirmed.

Entrepreneur and investor who co-founded Collab Capital and Goodie Nation. His current personal site places his Collab co-founder and Managing Partner work in the Previously section, separately from his current investment and community roles. No exact departure date is published.

Senior Investment Associate at Collab Capital, conducting market research, due diligence and portfolio support. Her background includes startup building at ACT House, entrepreneurship programming at Ed Farm and co-founding4WRDVentureCapital. Graduated from Florida A&M University and teaches entrepreneurship at Morehouse College.

Principal at Collab Capital, working on sourcing, due diligence and portfolio support. Previously invested at Vestigo Ventures and worked in corporate finance at Twitter and financial-institutions banking at JPMorgan. Graduated from Spelman College in economics and helped found BLCK VC’s Boston chapter.

Co-founder and Managing Partner of Collab Capital. Co-founded Partpic, developing computer-vision tools for identifying industrial parts, and sold it to Amazon in2016. Previously led Google for Startups in the United States, supporting underserved founders; graduated from Howard University.

Marcus Hui is vice president at GT Healthcare Capital Partners. His current primary biography says he joined in2021, with the exact month and day undisclosed. It describes earlier work helping startups at Hong Kong Science and Technology Parks, healthcare investing at a Beijing-based financial institution, and strategy and business development in medical technology and healthcare services. He studied biochemistry at Imperial College London and pharmacology at the University of Oxford. The2026 MedTech World Hong Kong programme and Startup World Cup’s own judges page independently identify his GT title; the latter supplies a genuine name-bound original publisher portrait rendition. His event affiliation does not imply any personal check.

Ping Wen is a venture partner at GT Healthcare Capital Partners with clinical and medical-device experience. His primary biography identifies an eight-year clinical-medicine MD programme completed in2010 at Peking Union Medical College and the Chinese Academy of Medical Sciences. It describes six years of neurosurgical work at Zhujiang Hospital and a2014–2015 visiting-scholar period at Siena University Hospital, followed by medical-device research and commercialization from2016. The biography’s patent and product-development counts are attributed to the publisher and do not establish regulatory approval or clinical efficacy. No genuine portrait was authenticated; the own-site name graphic is excluded.

Fred Aswad is a venture partner named by GT Healthcare Capital Partners. His primary manager biography describes biotechnology research and drug-discovery work at Bayer, including immuno-oncology programmes, followed by a senior biology position at IDEAYA Biosciences focused on small-molecule therapies and synthetic lethality. It identifies an immunology PhD from the University of Southern California. Apeiron Therapeutics’ current team page identifies him as chief scientific officer and supplies a genuine name-bound headshot. That page contains an unrelated sentence referring to Jim and a Duke degree; the inconsistent sentence is excluded. His outside scientific career does not establish personal investment allocations.

Lo Yuk Lam is chairman of GT Healthcare Capital Partners and a biotechnology industry leader with experience in company governance, research and public service. The manager’s public directory names him chairman, and a2026 HKEX-filed annual report corroborates a chairmanship beginning inJuly2019 without establishing an exact day. Hong Kong Biotechnology Organization’s current primary biography identifies him as its honorary founding chairman and connects the same person to GT; its name-bound original portrait is used here. His career includes biotechnology industry development and university advisory work. Older GT biographies list some board and government titles that have changed, so those are retained as published career history rather than asserted current appointments.

Jason Yeung is a partner named in GT Healthcare Capital Partners’ current public team directory. His primary biography describes more than twenty-five years of wealth-management and investment-banking experience, including executive positions at Credit Suisse, Merrill Lynch, JPMorgan and Goldman Sachs. It describes advising wealthy clients on equities, fixed income, derivatives, private equity and other investments, and building access to external asset managers. The reported assets managed in his previous career are not evidence of a GT fund raise. No exact appointment date, separately verified educational credentials or authentic portrait was established. The own-site name graphic is deliberately excluded as a human photograph.

Mingxi Li is a partner at GT Healthcare Capital Partners focused on life-science technology and cross-border commercialization. The manager describes earlier Jiuding healthcare investing and Simcere work, including a senior-director position in2013–2017. He studied biological science and biotechnology at Tsinghua University and earned a biochemistry PhD at the University of Illinois Urbana-Champaign. Apeiron Therapeutics’ current primary team biography identifies the same scientist as its CEO and a GT partner, providing a genuine name-bound portrait. His former Simcere portfolio responsibility is career history, not a GT fund closing or personal cash investment. He is distinct from an unrelated New York internal-medicine physician with the same name.

Alan Au is founder and managing partner of GT Healthcare Capital Partners, an Asia-based cross-border healthcare investment partnership. His published career includes healthcare investment banking at Deutsche Bank in2011–2012, JAFCO Asia in2008–2010, Morningside in2000–2005 and earlier KPMG financial-advisory work. The manager describes prior Simcere advisory work and Nepstar board service in2013–2016; these are historical affiliations. He studied psychology at the Chinese University of Hong Kong and management at Columbia Business School, and the manager reports US CPA and CFA credentials. Boundless Bio’s SEC-filed investor agreement identifies him as general partner signing for two separately named GT Nextgen funds. The authentic portrait is supplied by Moon Surgical’s current name-bound board-observer card. He is distinct from the HKMA banking-conduct executive of the same name.

Publicly named Board Director at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Publicly named Board Chair at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Publicly named Venture Manager at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Marco has built consolidated managerial and financial experience in the Life Sciences sector, serving as Country CFO and Oncology Region Europe CFO at Novartis. Over his career he has developed solid experience in supporting entrepreneurial and business-development initiatives, with a proven track record in financial management and in growing organisations across the healthcare and pharmaceutical sector.

Lorenzo has built significant experience in venture capital and alternative investments as Co-Founder and Managing Director of Alchimia Investments, contributing to the establishment and management of investment vehicles and to capital-raising activities. He has served as Managing Director and board member of portfolio companies and, as a founding-team member, took part in the launch of major projects such as Arsenale Group and Orient Express La Dolce Vita. He is also a lecturer and Venture Capital expert at Luiss University.

Publicly named Senior Advisor, Board Director at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Publicly named Senior Advisor at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Publicly named Operating Partner at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

He has built over 5 years of experience in mid-market M&A transactions at Deloitte Financial Advisory, where he actively contributed to more than 10 deals, both sell-side and buy-side, advising entrepreneurs, private equity funds and industrial operators. Over the course of his career he has developed expertise across the ICT and cybersecurity, software and artificial intelligence, telecommunications, agri-industrial and agri-tech, and energy services sectors. He holds a Bachelor's degree from ESCP Business School and a Master of Science in Corporate Finance & Banking from EDHEC Business School.

He joined Origine in May 2026 as Investment Manager, having built around nine years of experience in the Italian mid-market private equity sector. Following roles at Armònia SGR and Entangled Capital SGR, he has taken part in numerous majority investment transactions across different industrial sectors, following all their key phases, from analysing and structuring the investment to managing and enhancing portfolio companies. He has also supported the management of portfolio companies in implementing strategic and operational value-creation initiatives.

Tommaso brings over 23 years of experience in the financial sector, more than 18 of them in private equity as a principal investor in Italian and European mid-market funds. Over his career he has managed every phase of the investment process, from origination and deal structuring through to portfolio management and exit. He has held positions of growing responsibility at leading private equity firms, including Senior Director at Green Arrow Capital, Principal at Ergon Capital, Director at Alto Partners and Junior Partner at Armònia SGR, developing significant experience in growth, sector consolidation and value-creation transactions. Tommaso began his career in corporate finance at Deutsche Bank and Lazard, where he gained experience across numerous M&A transactions.

A professional with over 25 years of experience in the financial sector, more than 15 of them in Private Equity as a principal investor in investment funds and 10 years in investment banking at Deutsche Bank. Over his career he has held prominent roles in the Italian private equity market, including Investment Director at Clessidra SGR and Partner at Armònia SGR.

Daniel has built his career across data analysis, data infrastructure, and technical systems development, with experience spanning financial, operational, and client-facing environments. He has worked as a project and data lead at Deloitte and boutique firms in the FMCG sector, and more recently has led data pipeline strategy, product architecture and implementation, and client delivery within SaaS environments. He holds a Master’s degree in Physics from the University of Bristol.

Publicly named Executive Assistant at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Teresa Sanseverino is named in the fund-management function of Origine SGR, previously Innogest SGR, by its current public directory. The source does not disclose additional current responsibilities.

Marialiliana has built significant experience across administrative, financial and operational functions within the management of alternative investment funds, at leading asset managers active in private equity and venture capital. Over her career she has held senior roles including Chief Financial Officer, Chief Operating Officer and Head of Administration at firms such as Ambienta SGR, Hyle Capital Partners SGR and I2 Capital Partners SGR, also developing expertise in ESG and risk management. As Chief Financial Officer of the SGR, she oversees its administrative, financial and operational activities, contributing to process efficiency and regulatory compliance.

Investment banker, principal investor and entrepreneur with consolidated experience across the public and private sectors, with particular specialisation in telecommunications and digital transformation, energy and the agri-food supply chain. Over his career he has held senior roles, including Senior Managing Director at Macquarie, Senior Partner at Vitale & Co and Head of the Telecommunications Department at the Italian Ministry of Economic Development (MISE).

Ashish Narendra Patel, published professionally as Dr Ash Patel, was the Optum Ventures principal appointed to OxfordVR’s board in the February2020issuer financing announcement. Companies House records his full legal name and historical director term. Mercia’s own earlier professional interviews and authored life-sciences research corroborate the physician-investor career before Optum. He is distinct from the existing Kenya-based Antler fractional CTO Ashish Patel; no homonym merger or personal investment is inferred.

Deepak Gopalakrishna led OxfordVR during its later independent period, documented by his2022IVRHA speaker biography and its issuer announcements. His published biography reports an MBA and doctorate in genetics and molecular biology, earlier academic work on congenital disorders, healthcare entrepreneurship and work scaling BCG Digital Ventures. He also founded Rey, a distinct2021USmental-health company that announced plans to absorb OxfordVR. Exact receiving-entity allocations are not assumed from that business relationship.

Mavi Sánchez-Vives, formally María Victoria Sánchez-Vives, is a physician and neuroscientist who leads systems neuroscience at IDIBAPS as an ICREA research professor. Her own ICREA biography describes doctoral neuroscience training, postdoctoral work at Rockefeller and Yale, and co-direction of the Event Lab. Jason Freeman’s Oxford university biography explicitly names her as an OxfordVR co-founder. This scientific founding affiliation is historical, without an inferred current commercial position or personal investment.

Bernhard Spanlang is a computer-graphics and virtual-reality researcher named as an OxfordVR co-founder in Jason Freeman’s university biography. UCL documents his engineering doctorate in cloth modelling and visualization, involving physically based simulation and virtual clothing. His published professional profile describes later immersive-technology work at Kiin. The OxfordVR founding affiliation is historical and does not imply a present executive role or financial check.

Mel Slater is a virtual-environments scientist and OxfordVR scientific co-founder, explicitly named in Jason Freeman’s Oxford university biography. His published academic CV describes research leadership at Queen Mary, UCL and Barcelona and work on presence and embodiment in virtual environments. He is distinct from an unrelated US Army namesake. His OxfordVR statutory directorship ended in2017; a historical founding affiliation is not a current company management position.

Dean Noakes was OxfordVR’s IT manager according to its historical public company directory. His own professional profile and a colleague recommendation corroborate that OxfordVR work, alongside a later Qube Research & Technologies affiliation. This record retains the historical technical-support role; no current OxfordVR employment, precise dates or unverified academic qualifications are asserted.

Polly Haselton is a cognitive behavioral therapist named as OxfordVR’s psychologist in its historical directory and an author of its2018height-phobia clinical study. Her own practice biography describes Cardiff psychology training and postgraduate psychological-therapy study at Exeter and Oxford, together with NHS and research work. Her later published career includes other digital-health organizations. The historical OxfordVR role does not establish current employment.

Aitor Rovira is an Oxford virtual-reality technology researcher whose work combines computer science, immersive interaction and psychology. His university biography describes a UCL computer-science doctorate, postdoctoral research at Japan’s Nara Institute of Science and Technology, and joining Oxford in2017. He supervises software and hardware for therapeutic research and trials. OxfordVR’s older directory names him head of VR strategy; that historical commercial affiliation is distinct from his university role.

Andrew Forster was OxfordVR’s lead artist according to its published historical directory. His own professional profile is corroborated by Sam Gage’s recommendation naming the OxfordVR lead environment artist role. This is the immersive-therapy visual artist, not another similarly named investor or engineer. The source does not verify a current OxfordVR role, degree or exact employment dates.

Thiago Craveiro, also professionally published as Thiago Escudeiro Craveiro, was a programmer on OxfordVR’s historical team. The company directory lists that role, and his own profile carries colleagues’ recommendations identifying him as the first programmer in Sam Gage’s OxfordVR team. His published profile also describes software and iOS development. Exact company dates and a current OxfordVR position are not inferred.

Sam Gage led virtual-reality development at OxfordVR according to the company’s published historical directory. His professional profile and colleagues’ published recommendations corroborate leadership of its Unity-based therapeutic VR development team. The affiliation is historical; current OxfordVR employment, exact dates and educational qualifications are not established by the available primary company biography.

Lars is published as a nomination-committee member appointed by Cajelo Invest Ltd. This shareholder-governance role is distinct from operating employment.

Mattias is published as a nomination-committee member representing the Fourth Swedish National Pension Fund. This is a shareholder-governance affiliation, not Flerie employment.

Jenni is a board member with chemistry and life-sciences policy experience. Her published biography identifies prior government and innovation-agency duties.

Holger joined the board in2026. Flerie describes his molecular-biology background and external biopharmaceutical business-development and alliance-management experience.

Anders is a board member with medical and pharmaceutical-development experience, including prior global medicines-development leadership at AstraZeneca.

Cecilia is a board member and audit-committee chair. Her published experience includes finance, corporate relations and life-sciences leadership.

Thomas founded the Flerie investment platform in2011 and is its executive chairman. He previously co-founded Recipharm and participates in Flerie’s board committees.

Ted is CEO and a management-team member. His background includes biotechnology research, clinical research and strategy consulting, with earlier portfolio-company leadership.

Paula joined in January2024. Her background includes finance, private equity, analysis, business development and founding a Swedish startup.

Michaela is published as head of investor relations and described as a senior adviser. She has finance and fundraising experience and separately works as an independent consultant.

Mark is a partner and management-team member with business-development, M&A and supply-chain experience, including prior Recipharm leadership.

Manuela joined in June2025 as assistant to CEO Ted Fjällman, following support roles in insurance and other industries.

José is a US-based venture partner. His published biography describes life-sciences transactions, executive leadership and legal experience.

Fredrik joined as senior adviser in2026. His background includes drug-development operations, research, manufacturing and biotechnology company-building.

Cecilia leads finance and serves as deputy CEO. The current management biography distinguishes appointments at the listed company in2024 from earlier Flerie Invest duties.

Carl-Johan has been a senior adviser since April2021. His published background includes pharmacology and a long career at Recipharm.

A physical chemist and biotech executive, Arvid joined Flerie as venture partner in2026. Flerie separately identifies him as Empros Pharma’s CEO.

Christophe Faucherand is a healthcare product leader listed as OxfordVR’s chief product officer in its historical company directory. His own professional profile describes more than15years building products and a later electronRx affiliation. This record preserves the source-published OxfordVR product role without asserting current employment or an unverified appointment date; additional degree and career details are not supplied by the company directory.

Katie Bedborough was OxfordVR’s finance and operations leader during its independent fundraising period. The Oxford Trust’s January2020 interview identifies her as both COO and CFO, while the February2020 issuer financing announcement credits her work on the completed Series A. The old directory lists CFO. Her historical statutory director term is documented by Companies House; no current standalone OxfordVR executive position or undisclosed education is assumed.

Jason Freeman is a virtual-reality treatment designer in Oxford’s Cognitive Approaches to Psychosis group. His own university biography describes work on Phoenix, gameChange, height and needle phobia treatments, and the digital Feeling Safer intervention. It explicitly names him as an OxfordVR co-founder alongside Daniel Freeman, Mel Slater, Bernhard Spanlang and Mavi Sánchez-Vives. OxfordVR’s older public directory lists him as COO. The historical company role and statutory director term are separate from his current academic work.

Barnaby Perks is an engineer and digital-health entrepreneur who led OxfordVR before its later business combinations. Its 2018 and February2020 announcements name him as CEO; the old company website is therefore treated as a historical roster. His published Digital Youth biography describes biomedical engineering research at Dundee, assistive-technology development and founding leadership of Ieso. He became St John’s Innovation Centre CEO in April2024. The Companies House record supplies the separate historical OxfordVR statutory director term.

Andrea Bianchi heads strategy, industrial policy and sustainability at Invitalia. The agency’s own September2025 FondoCresciAlSud event announcement expands his full name and responsibility, resolving A.Bianchi in its May2026 first-line organization chart. Invitalia’s May2024 sustainability announcement also identifies his strategic-planning and industrial-policy responsibilities. He discusses public development finance, industrial transition and sustainability; no personal venture investment or individual portfolio board role is inferred.

Adam Workman heads Oxford University Innovation Investments and New Ventures and represents the University of Oxford as shareholder across its spinout and startup interests. He has supported early-stage companies since2000 across clean technology, engineering, software and life sciences. His earlier career included partnership at350 Investment Partners, and his education includes natural sciences.

Simon Warner heads Oxford University Innovation Licensing and Ventures for Life Sciences. He joined in2021 with more than25 years of biotechnology experience spanning venture capital, strategic partnerships and intellectual property. He previously served as Oxitec chief scientific officer before its2015 acquisition by Intrexon.

Russell Wallace heads Oxford University Innovation Finance, having joined in July2023. His remit includes financial planning and reporting, accounts, audit, tax compliance and financial controls. An ACCA-qualified accountant, he works with senior leadership and directors on governance and strategic decisions.

Brendan Ludden heads Oxford University Innovation Licensing and Ventures for Physical Sciences. Since joining in July2017, he has led commercialisation and supported student and alumni entrepreneurship through the incubator. His team supports ventures, licensing and inventors bringing university research to market; he studied at Oxford and Cambridge.

Carolyn Hall heads Oxford University Innovation People and Culture. She joined in February2012 after leading HR and facilities at Marks and Spencer, and previously worked for Dixons Retail and WH Smith. Her published experience spans people management, HR and organisational strategy across retail and distribution.

Helen Foster heads Oxford University Innovation Operations. She joined OUI in January2020 and coordinates systems, processes and governance supporting performance and compliance. Previous operational leadership at Audley Travel and Hellios Information informs her work on organisational improvement and cross-functional projects.

Georgia Broome heads Oxford University Innovation Communications and Marketing. She joined OUI in May2025, overseeing marketing, strategic communications and public relations. Her earlier Oxford work included strategic communications leadership in Computer Science and management of the Social Sciences Connected Communications Service.

Kirsty Allen heads Oxford University Innovation Consulting Services, having joined OUI in February2025. Her earlier Oxford research-management work began in2009 and included programme management in the Nuffield Department of Medicine’s Modernising Medical Microbiology Unit and advising the university’s Research Excellence Framework2021 submission.

Jaci Barnett is Oxford University Innovation Chief Operating Officer, leading licensing, ventures, consultancy and operations activities that protect and commercialise university research. She previously led research commercialisation and investment at Bristol and held senior technology-transfer roles at Nelson Mandela University and Wits University in South Africa.

Matthew Wood is an Oxford University Innovation non-executive director and Oxford Professor of Neuroscience. His team at the Institute of Developmental and Regenerative Medicine develops genetic medicines for rare neurological, neuromuscular and heart disorders. He leads the Laboratory of RNA Biology and Neuromuscular Disease, researching RNA-based therapeutic approaches.

Louise Slater is an Oxford University Innovation non-executive director and Oxford Professor of Hydroclimatology. As Social Sciences Division Associate Head for Research and Impact, she has responsibilities spanning15 departments and innovation portfolios including ESRC, environment and humanities impact-acceleration accounts.

Angela Kukula is an Oxford University Innovation non-executive director, MedCity CEO and London & Partners Director of Life Sciences. Her work supports growth and commercialisation across the London life-sciences ecosystem. Previous roles included commercial leadership at Chelsea and Westminster Hospital and business and innovation leadership at the Institute of Cancer Research.

Karin Immergluck is an Oxford University Innovation non-executive director. She leads Stanford’s Office of Technology Licensing as Associate Vice Provost, overseeing intellectual-property management. Her earlier University of California technology-transfer career included executive leadership of UCSF’s Office of Technology Management, and her official biography identifies doctoral training in developmental biology.

Kohei Wakamatsu (若松 康平) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns operations, business planning and consulting education. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Koji Harada (原田 幸治) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns leadership of the Fukuoka general branch. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Kazuhiko Deyama (出山 和彦) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns East Japan markets and corporate sales. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Yasuhiko Shinkai (新開 保彦) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns customer-experience promotion and sales promotion. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Kentaro Tanaka (田中 健太郎) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns Chubu markets and corporate sales, heading the Chubu sales division. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Reiko Abe (阿部 玲子) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns leadership of the metropolitan consulting-sales office. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Teruyuki Nishimura (西村 輝幸) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns East Japan markets and Hokkaido/Tohoku corporate sales. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Katsushi Makiuchi (牧内 克司) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns real-estate and finance/investment activities. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Jun Miyamoto (宮本 淳) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns Chief Financial Officer, with management planning, accounting and revenue-management responsibilities. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Koichiro Yoshida (吉田 浩一郎) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns human resources, sales personnel and general affairs. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Katsufumi Kubo (久保 克文) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns agency operations and financial-institution business. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Tetsunori Kano (加納 哲訓) is listed as Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns shared metropolitan-area corporate sales responsibility. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Shivakumar Ramaraj (シヴァクマール・ラマラジ) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns Chief Information Officer, with IT planning responsibility. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Takashi Uehara (上原 高志) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns insurance-contract medical matters, contract services and insurance claims. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Masaki Eto (江藤 正樹) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns West Japan markets and Kyushu/Okinawa corporate sales. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Yasuyuki Watanabe (渡辺 康幸) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns asset formation/succession, group pensions and defined-contribution/investment-trust promotion. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Jun Kuroda (黒田 潤) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns digital transformation, business-process planning, customer success and contact-centre functions. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Hideyuki Ohashi (大橋 秀行) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns Chief Risk Officer, including risk management and general credit assessment. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Kazuhiro Osawa (大澤 和浩) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns metropolitan Tokyo markets and regional corporate sales. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Ken Mikami (三上 研) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns West Japan markets and Chugoku/Shikoku corporate sales. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Makoto Goda (合田 真) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns individual and group protection businesses. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Miki Kashizaki (柏崎 美樹) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns life-industry, media, transport/infrastructure, services and electronics corporate accounts. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Koichi Nishiyama (西山 幸一) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns wide-area corporate sales, public entities and industrial/infrastructure corporate accounts. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Takahito Shibuya (渋谷 孝人) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns Kansai markets and corporate sales, serving as head of the Kansai sales division. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Takashi Iida (飯田 貴史) is listed as Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns investment planning, invested-asset management and designated separate-account operations. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Yoshitaka Okumura (奥村 嘉孝) is listed as Senior Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns wholesale business oversight, corporate services and corporate solutions. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Masahiko Yamauchi (山内 正彦) is listed as Outside Audit & Supervisory Board Member of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The role concerns statutory audit and supervision, distinct from operational venture investment leadership. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Akira Ishihara (石原 明) is listed as Outside Audit & Supervisory Board Member of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The role concerns statutory audit and supervision, distinct from operational venture investment leadership. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Hiroshi Azuma (東 浩) is listed as Outside Audit & Supervisory Board Member of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The role concerns statutory audit and supervision, distinct from operational venture investment leadership. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Yoshifumi Wakayama (若山 吉史) is listed as Full-time Audit & Supervisory Board Member of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The role concerns statutory audit and supervision, distinct from operational venture investment leadership. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Shigeru Mori (森 茂) is listed as Full-time Audit & Supervisory Board Member of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The role concerns statutory audit and supervision, distinct from operational venture investment leadership. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Yoshiyuki Suzuki (鈴木 義幸) is listed as Outside Director of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The outside-director appointment is a non-executive corporate governance affiliation. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Naomi Ushio (牛尾 奈緒美) is listed as Outside Director of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The outside-director appointment is a non-executive corporate governance affiliation. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Takehiko Nakao (中尾 武彦) is listed as Outside Director of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The outside-director appointment is a non-executive corporate governance affiliation. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Hironori Takahashi (高橋 宏典) is listed as Director of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. This is a board-level corporate governance affiliation, distinct from an automatically assumed venture-fund management role. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Tetsuya Kikuta (菊田 徹也) is a director of Daiichi Life Insurance Co., Ltd. as of1October2026 and separately the parent Daiichi Life Group’s president/group CEO. His current English biography traces his1987 joining date, insurer executive work and subsequent group finance and leadership roles. It explicitly warns that pre- and post-October2016 operating insurers are different legal companies. His personal board affiliations do not substitute the holding company for the insurer as a2019 Neurotrack investor.

Atsuko Ochiai (落合 敦子) is listed as Director & Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns Chief Compliance Officer, with legal and compliance oversight. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Shoji Takeuchi (竹内 章二) is listed as Director & Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns Chief Internal Audit Officer, covering internal audit and investigation/public-relations departments. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Kohei Kai (甲斐 講平) is listed as Representative Director & Senior Managing Executive Officer of Daiichi Life Insurance Co., Ltd. in the operating insurer’s official roster dated1October2026. The same-day responsibilities document assigns overseeing the retail business and shared operations responsibility. The Japanese spelling and published reading identify this person; unrelated namesakes, unverified qualifications and individually allocated startup checks are excluded.

Toshiaki Sumino (隅野 俊亮) is Representative Director and President of Daiichi Life Insurance Co., Ltd. on the operating insurer’s1October2026 roster. The parent’s current English biography confirms the insurer presidency and separate parent directorship. He joined the mutual insurer in1992 and served in group executive roles before becoming a group director in2023. His public leadership identity is distinct from an individually allocated impact-investment check.

Seiji Inagaki (稲垣 精二) chairs the board of Daiichi Life Insurance Co., Ltd. as of1October2026. The parent’s current English leadership biography independently confirms this insurer chairmanship, alongside his separate group board chair role. He joined the mutual insurer in1986 and held executive/leadership roles before the2016 holding-company restructuring. The pre- and post-October2016 insurers are legally different companies; the career continuity does not turn the current insurer into the parent. No personal Neurotrack check is inferred.

Patrick Grant is an Oxford University Innovation non-executive director, Vesuvius Chair of Materials and Oxford Pro-Vice-Chancellor for Research. He previously led the Department of Materials and held divisional leadership responsibilities. Elected a Royal Academy of Engineering fellow in2010, he works on research strategy and external funding. This qualified academic profile is not assigned to the pre-existing Signal/Outlier Ventures namesake.

Robert Easton is an Oxford University Innovation non-executive director. His biography describes prior Oxford Pro-Vice-Chancellor responsibilities for development and external affairs and 19 years at Carlyle as a global partner and investment professional. It also identifies senior-adviser and investment-committee work at Oxx and Melior Equity Partners; those separate capacities do not establish personal investment checks.

Keith Channon is a non-executive director of Oxford University Innovation, Field Marshal Earl Alexander Professor of Cardiovascular Medicine and head of Oxford’s Radcliffe Department of Medicine. He is an honorary consultant cardiologist at the John Radcliffe Hospital, directs Oxford Academic Health Partners and chairs the NIHR-BHF Cardiovascular Partnership. His biography also describes former NIHR Oxford Biomedical Research Centre leadership.

Mairi Gibbs is Chief Executive Officer and Executive Director of Oxford University Innovation. She has worked at OUI since 2002, with responsibilities across operating systems, processes, post-deal management, intellectual property, reporting, IT transformation and compliance. Her technology-transfer work includes spinout formation, licensing, partnership management and academic outreach.

Nicola Blackwood chairs Oxford University Innovation, having joined as chair in 2021. Her official biography describes life-sciences and innovation leadership, chair roles at Genomics England and the Health Data Research Service, board service at BioNTech and RTW Biotech Opportunities, and membership of the Oxford Harrington Rare Disease Centre advisory council. She previously served in government and is a member of the House of Lords.

Lomax Ward, legally Lomax Blois Ward in the primary company register, co-founded Luminous Ventures and was a partner in its2018 launch. His primary Kauffman Fellows biography describes current work as an Outsized Ventures general partner and co-founder backing European pre-seed and seed deep-tech founders, a Classics degree from Cambridge and subsequent London law-school training. A dated2023 own-manager biography identifies prior corporate-law work at Slaughter and May, Luminous investment experience and co-founding the ALLOCATE venture-manager community. His current legal directorship of company11416023 dates from June14,2018, while the Luminous fund name itself is historical and fully deployed. His authentic name-bound Kauffman portrait is distinct from namesake investors.

Isabel Fox, also known professionally as Izzy Fox in the Oxford VR financing announcement, co-founded Luminous Ventures with Lomax Ward and was a partner in its2018 firm launch. Her primary UKRI biography, updated September2023, describes deep-tech investing since2015, prior White Cloud Capital and Luminous work, corporate public-relations entrepreneurship and software-startup experience. It also described an Innovate UK Council appointment and Outsized affiliation at that date; these are dated biography statements, not inferred current appointments. Companies House shows her management-company directorship June14,2018–May8,2024. The deployed legacy Luminous fund has no current published live team, so her Luminous affiliation is explicitly historical.

Domenico Tudini is a publicly named officer responsible for financial reporting (appointment july28,2023) at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Pasquale Ambrogio is a publicly named head of anti-corruption, transparency, anti-money-laundering and compliance at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Beniamino Bimonte is a publicly named chief operating officer (may2026 organization chart) at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Francesca Ottier heads fund management and equity investments at Invitalia according to its May2026 organization chart and current own recruitment publisher. This current agency affiliation is distinguished from her previously published ItaliaVentureII responsibilities at CDP Venture Capital. Existing authentic portrait, professional biography and external manager roles are preserved; a precise departure date from any prior affiliation is not guessed.

Luigi Gallo is a publicly named head of public advisory (may2026 organization chart) at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Giovanni Portaluri leads public investments at Invitalia, as shown on its May2026 organization chart and corroborated by the agency’s own infrastructure announcements. Earlier published work concerned competitiveness, infrastructure and territories. The current role concerns public investment implementation rather than a personal venture fund or individual equity portfolio.

Stefano Piccaluga is a publicly named head of large investments (may2026 organization chart) at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Leonarda Danila Sansone is a publicly named head of enterprise development (may2026 organization chart) at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Valentina Lazzareschi is a publicly named head of legal affairs and governance (may2026 organization chart) at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Dario Lioto is a publicly named head of administration and finance (may2026 organization chart) at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Francesca Daniela Gentile, also professionally called Daniela Gentile, leads institutional relations and communication at Invitalia. The May2026 organization chart uses F.Gentile; official Italian parliamentary hearing records expand the full name and identify the same responsibility. Invitalia’s own current public posts additionally describe responsibility for the research centre. She represents the agency in startup-network and investment-attraction events; no portfolio board membership or personal investment is inferred.

Paolo Foglia is a publicly named head of internal auditing (may2026 organization chart) at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Serena Maria Viggiano is a publicly named alternate statutory auditor at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Marco Canzanella is a publicly named alternate statutory auditor at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Sergio Di Meo is a publicly named statutory auditor at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Massimo Mariani is a publicly named statutory auditor at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Antonella Tomei is a publicly named chair of the board of statutory auditors at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Gianluca Vesentini is a publicly named board director at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Stefania Pastore is a publicly named board director at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Claudia Colaiacomo is a publicly named board director at Invitalia, Italy’s state-owned national development agency. The official published governance directory, regulatory disclosure or May2026 first-line organization chart establishes this scoped affiliation. A broader career history and genuine individual portrait are not exposed by that role source, so education, external mandates, investment ownership and tenure dates are not inferred.

Bernardo Mattarella has been chief executive of Invitalia sinceJuly2022 and was reappointed in2025. His official biography describes prior leadership of Mediocredito Centrale during2017–2022, Invitalia Incentives and Innovation during2011–2017, and earlier chief-financial-officer work. He previously worked in banking and Arthur Andersen. The current original portrait is explicitly named by Invitalia.

Sergio Schisani is president of Invitalia, with appointment recorded onJune30,2025 and the official biography describing the presidency fromJuly2025. His prior professional career covers real-estate investment management and infrastructure, including TorreSGR, Generali Properties and DoRe. The current original portrait is explicitly named by Invitalia.

Lauren Leonhardt is a Louisville business professional who publicly described celebrating two years at Thornton Capital in a historical own-profile post. The January–March 2023 newsletter of Visually Impaired Preschool Services independently identifies her as one of Thornton Capital’s team members in its account of a charitable award presentation. Her current public profile instead identifies Lifetime Financial Growth, so ongoing Thornton employment and a present chief-operating-officer title are not asserted. She announced completing an MBA at Bellarmine University in 2023. No precise departure day or personal equity check is inferred.

Oliver Brown is a Louisville finance professional affiliated with Thornton Capital. The firm’s own public employee caption identifies him as finance manager. His public professional profile describes work in mergers and acquisitions, valuation, financial analysis and financial modelling and records study at the University of Denver’s Daniels College of Business during 2015–2016, including participation in the Marsico Fund and DU Solar. The accessible profile lists a Series 79 credential. Exact current regulatory registration, employment dates and transaction allocations are not established by those disclosures.

Toni Capito is a Louisville professional publicly affiliated with Thornton Capital. The firm’s own public company-profile caption describes her experience supporting C-level executives and their teams; her individual public profile identifies Thornton Capital as her employer. The accessible primary material does not establish her exact internal job title, tenure-start day, educational history or complete earlier career. The affiliation is retained at that published scope, without assigning investment-decision authority or a personal portfolio-company check.

Sam Crockett is a Louisville investment professional whose public profile identifies Thornton Capital. The family office’s own public company-profile employee caption describes him as a senior investment manager. His individual profile lists Cornell University study for 2025–2027. The accessible material does not disclose a complete earlier career, an exact employment-start day or particular investment responsibilities, so those details remain unverified. His employment does not establish an individual cash contribution to portfolio companies.

Michael Lynch is a Louisville finance professional publicly affiliated with Thornton Capital. The 2025 Finance Futuring Panel report published by MBA Research and the Kentucky Department of Education explicitly lists him as the firm’s chief financial officer; his public professional profile continues to identify Thornton Capital. He studied at the University of Kentucky and lists a CPA credential issued in September 2000. His own public material discusses finance automation and artificial intelligence. An exact public tenure-start day and complete career chronology are unavailable. He is distinct from unrelated people with the same name; no personal investment is inferred from this employment.

Tom Jones is president and chief investment officer of Thornton Capital and a founding principal of Platform Real Estate Group. That venture’s primary biography states that he oversees the family office’s investment strategy, risk management and business development. His earlier career included relationship-management, business-development and credit positions at JPMorgan Chase and Wells Fargo, following experience at Deloitte. The biography records an MBA from UNC Chapel Hill and undergraduate degrees in economics and German from Sewanee. No exact employment start day or personal financing allocation is publicly established.

Matt Thornton is the founder and principal of Thornton Capital, a Louisville single-family investment office launched after the 2019 sale of the Thorntons convenience-store business. The primary biography published by Platform Real Estate Group identifies him as a founding principal of that real-estate venture and records his 2001–2019 service as president and CEO of Thorntons. He also provided seed backing to Chicago real-estate investor L3 Capital in 2009. Endeavor identifies him as a regional board chair. These operating-company sales, outside roles and seed commitments are not recorded as cash raised by Thornton Capital. The unrelated Rapta executive Matthew D. Thornton remains a separate person.

Tetsuya Morito is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; in charge of Overseas M&A; General Manager, Global Strategy Department. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Yoshihiro Sasano is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; in charge of Public Relations; General Manager, Corporate Communications Department. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Sina Martens is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; in charge of Communications; (Group Head of Communications). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Richard Higa is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; Group Deputy CAE; General Manager, Internal Audit Department. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Yohei Namiki is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; Deputy CEO of SOMPO Wellbeing. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Junsuke Koike is listed in Sompo Holdings’ official October1,2026 leadership directory as Executive Vice President; Group Deputy CFO. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Nicolas Burnet is listed in Sompo Holdings’ official October1,2026 leadership directory as Executive Vice President; in charge of SOMPO P&C; Group Deputy CFO. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Hiroshi Horie is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Executive Vice President; in charge of Compliance. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Ryoko Shimokawa is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; in charge of Wellbeing Business; (President and Representative Director, Sompo Health Support). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Katsuyuki Ohara is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; in charge of Digital Business; (Palantir Technologies Japan CEO). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Katsuhito Nakagawa is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; in charge of Direct Insurance Business; (President and Representative Director, Sompo Direct Insurance). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Kyotaro Hirose is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; Head of Direct Insurance Business; General Manager, Office of Group CEO. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

David Camputo is listed in Sompo Holdings’ official October1,2026 leadership directory as Group CAE; Senior Vice President. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Yoshiyasu Suzuki is listed in Sompo Holdings’ official October1,2026 leadership directory as Group CIO; Executive Vice President; General Manager, IT Strategy Planning Department. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Akiko Murakami is listed in Sompo Holdings’ official October1,2026 leadership directory as Group CDaO; Executive Vice President. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Ryuichi Yoshimura is listed in Sompo Holdings’ official October1,2026 leadership directory as Group Co-CDO; Executive Vice President; in charge of Wellbeing Business (Chief Digital & AI Officer). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Masayuki Kimura is listed in Sompo Holdings’ official October1,2026 leadership directory as Group Co-CDO; Executive Vice President. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Koji Takahashi is listed in Sompo Holdings’ official October1,2026 leadership directory as Group CRO; Executive Vice President and Executive Officer. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Kayoko Sakai is listed in Sompo Holdings’ official October1,2026 leadership directory as Group CSuO; Senior Executive Vice President. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Koichi Narasaki is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Executive Vice President and Executive Officer; Head of Digital ＆ New Business; in charge of Investment. The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Takamitsu Washimi is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; Head of Nursing Care Business under SOMPO Wellbeing Business; (President, Representative Director and CEO of Sompo Care). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Yasuki Kume is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; Head of Domestic Life Insurance Business under SOMPO Wellbeing Business; (President, Representative Director and CEO of Sompo Himawari Life Insurance). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Koji Ishikawa is listed in Sompo Holdings’ official October1,2026 leadership directory as Senior Vice President; Head of Domestic P&C Insurance Business under SOMPO P&C; (President, Representative Director and CEO of Sompo Japan Insurance). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Yasuhiro Oba is listed in Sompo Holdings’ official October1,2026 leadership directory as CEO of SOMPO Wellbeing, Senior Vice President; (Chairman of Sompo Himawari Life Insurance). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

James Shea is listed in Sompo Holdings’ official October1,2026 leadership directory as CEO of SOMPO P&C, Senior Vice President; Head of Overseas Insurance and Reinsurance Business under SOMPO P&C; (CEO of Sompo International Holdings). The published appointment defines a parent-group executive responsibility; the directory also identifies concurrent operating-company responsibilities where applicable. A full career chronology and exact joining date are not published on the reviewed parent directory, so earlier employers, education and personal investment authority are not inferred. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Shinobu Imamura is listed in Sompo Holdings’ official October1,2026 leadership directory as Director; Member of the Audit Committee. Imamura joined Yasuda in1995 and subsequently led group risk management. Her official biography records audit and supervisory responsibilities at Sompo Japan inApril2025 and appointment to Sompo Holdings’ board inJune2025. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Yuji Kawauchi is listed in Sompo Holdings’ official October1,2026 leadership directory as Director; Member of the Audit Committee. Kawauchi joined Yasuda in1988 and later led global business planning and Sompo Holdings Asia. He served in senior group executive and CEO-advisory positions before becoming a parent-company director inJune2025. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Jeffrey Hayman is listed in Sompo Holdings’ official October1,2026 leadership directory as Independent Outside Director. Hayman has international insurance leadership experience spanning Travelers and AIU/AIG, including personal-lines operations in the United States and Asia. His official biography records a Cytora advisory appointment in2023 and Sompo parent, Sompo Life Re and Sompo International board appointments inJune2026. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Toru Kajikawa is listed in Sompo Holdings’ official October1,2026 leadership directory as Independent Outside Director; Member of the Audit Committee. Kajikawa joined Chuo Audit Corporation in1976 and qualified as a certified public accountant in1979. His audit and professional-services career includes Grant Thornton Taiyo leadership. He joined Sompo’s board in2023. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Masayuki Waga is listed in Sompo Holdings’ official October1,2026 leadership directory as Independent Outside Director; Member of the Audit Committee. Waga joined Mitsubishi Kasei in1981 and subsequently held management positions across Mitsubishi Chemical’s Asian businesses. His later leadership includes Spiber, where the official biography records executive and chairman appointments in2025. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Meyumi Yamada is listed in Sompo Holdings’ official October1,2026 leadership directory as Independent Outside Director; Chair of the Nomination Committee; Member of the Compensation Committee. Yamada’s early career included Koei Kogyo and Kiss Me Cosmetics. Her professional experience in consumer and beauty businesses supports her independent oversight responsibilities. She joined Sompo’s board in2021 and Seven & i Holdings’ board in2022. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Misuzu Shibata is listed in Sompo Holdings’ official October1,2026 leadership directory as Independent Outside Director; Chair of the Audit Committee. Shibata qualified as an attorney in2000 and became a partner lawyer at NS Law Office in2001. Her outside-director and audit experience includes Sompo from2020 and Pilot Corporation from2023. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Kazuhiro Higashi is listed in Sompo Holdings’ official October1,2026 leadership directory as Independent Outside Director; Chairman of the Board; Chair of the Compensation Committee; Member of the Nomination Committee. Higashi began at Saitama Bank in1982 and later led Resona Holdings and Resona Bank as president and representative executive. He joined Sompo’s board in2020, brings banking and corporate-management experience, and has also held senior business-association and external board appointments. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Katsuyuki Tajiri is listed in Sompo Holdings’ official October1,2026 leadership directory as Director; Group CFO, Director, Deputy President and Representative Executive Officer. Tajiri joined Yasuda in1990. His subsequent leadership spans global business planning, group strategy and corporate planning, and executive management at Sompo Japan. He became Group CFO inApril2026 and joined the parent board inJune2026. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Shinichi Hara is listed in Sompo Holdings’ official October1,2026 leadership directory as Director; Group CHRO, Director, Deputy President and Representative Executive Officer; Member of the Nomination Committee; Member of the Compensation Committee. Hara joined Yasuda in1988 and later led global business planning. He became Group CHRO in2019, joined the Sompo International board in2022 and advanced to the parent board and representative executive leadership in2024–2025. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Mikio Okumura is listed in Sompo Holdings’ official October1,2026 leadership directory as Director; Group CEO, Director, President and Representative Executive Officer. Okumura started his insurance career at Yasuda in1989, subsequently worked in investment banking at FinTech Global and returned to group leadership. His experience includes leading Sompo Care and Sompo International, followed by Group COO in2022 and Group CEO in2024. The parent holding company is distinct from its insurance, care and health-support subsidiaries and from any standalone venture vehicle.

Hope King is listed in Backpack Healthcare’s clinical directory with the published credential LMSW. The own individual profile supplies a clinical biography and areas of practice.

Amala Okoye is listed in Backpack Healthcare’s clinical directory with the published credential LMSW. The own individual profile supplies a clinical biography and areas of practice.

Sundi Crosswhite Shelton is listed in Backpack Healthcare’s clinical directory with the published credential MSW. The own individual profile supplies a clinical biography and areas of practice.

Phoebe Renee White is listed in Backpack Healthcare’s clinical directory with the published credential LLMSW. The own individual profile supplies a clinical biography and areas of practice.

Ebony Jones is listed in Backpack Healthcare’s clinical directory with the published credential LCSW. The own individual profile supplies a clinical biography and areas of practice.

Melody Fakhourie is listed in Backpack Healthcare’s clinical directory with the published credential MSW. The own individual profile supplies a clinical biography and areas of practice.

Kayla King is listed in Backpack Healthcare’s clinical directory with the published credential NP. The own individual profile supplies a clinical biography and areas of practice.

Asia Caldwell is listed in Backpack Healthcare’s clinical directory with the published credential Nurse Practitioner. The own individual profile supplies a clinical biography and areas of practice.

Taijha Brummell is listed in Backpack Healthcare’s clinical directory with the published credential LMSW. The own individual profile supplies a clinical biography and areas of practice.

Eugene L. VanBurch is listed in Backpack Healthcare’s clinical directory with the published credential LCSWC. The own individual profile supplies a clinical biography and areas of practice.

Sarah Andoh-Kesson is listed in Backpack Healthcare’s clinical directory with the published credential LMSW-Master. The own individual profile supplies a clinical biography and areas of practice.

Yasmin Cespedes-Zaman is listed in Backpack Healthcare’s clinical directory with the published credential LMSW-Master. The own individual profile supplies a clinical biography and areas of practice.

Charmaine Conner is listed in Backpack Healthcare’s clinical directory with the published credential LPC. The own individual profile supplies a clinical biography and areas of practice.